Serviscope acquires Virginia ISO
Independent service organization Serviscope has expanded its reachin the northern Virginia, Washington, DC, and Baltimore areasby acquiring Certified X-ray, a small ISO based in Centerville,VA. Serviscope, of Wallingford, CT, said the acquisition is
Independent service organization Serviscope has expanded its reachin the northern Virginia, Washington, DC, and Baltimore areasby acquiring Certified X-ray, a small ISO based in Centerville,VA. Serviscope, of Wallingford, CT, said the acquisition is partof its plan to expand into new regional markets.
Certified X-ray focuses on maintaining GE x-ray equipment andspecializes in x-ray room moves and on-site refurbishing, accordingto Thomas Tierney, Serviscope CFO. The company also has severaltime-and-materials service contracts with luminary hospitals.
Serviscope was attracted to Certified because it offered accessto a market in which Serviscope did not have a presence. The acquisitionwas made using Serviscope stock and the company will bring allCertified employees under its wing, including president ScottStarkey.
Serviscope continues to target new acquisitions as part ofits growth strategy. The company is primarily looking at ISOsin new regional markets and at in-house service departments athospitals, Tierney said. Serviscope unveiled its AssetCare multivendorservice and asset management program in May, and plans to useacquisition to expand the types of equipment it is capable ofservicing under the program (SCAN 6/21/95).
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
